Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Buy
79
FOLD Quote, Financials, Valuation and Earnings
Last price:
$14.22
Seasonality move
:
4.76%
Day range:
$14.18 - $14.22
52-week range:
$5.51 - $14.36
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
7.27x
P/B ratio:
19.03x
Volume:
17.9M
Avg. volume:
12.7M
1-year change:
44.41%
Market cap:
$4.4B
Revenue:
$528.3M
EPS (TTM):
-$0.04
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
FOLD
Amicus Therapeutics, Inc.
|
$165.7M | $0.12 | 20.08% | 236.17% | $15.25 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$277.2M | $0.15 | 12.96% | -83.59% | $29.79 |
|
ANIP
ANI Pharmaceuticals, Inc.
|
$212.9M | $1.77 | 21.97% | 68.6% | $109.25 |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$780.4M | $0.34 | 11.37% | 43.52% | $89.74 |
|
CRMD
CorMedix, Inc.
|
$86M | $0.63 | 308.6% | 219.78% | $19.00 |
|
GILD
Gilead Sciences, Inc.
|
$7.5B | $2.14 | 1.49% | 33.42% | $132.38 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
FOLD
Amicus Therapeutics, Inc.
|
$14.21 | $15.25 | $4.4B | -- | $0.00 | 0% | 7.27x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$27.83 | $29.79 | $4.7B | 17.91x | $0.00 | 0% | 4.48x |
|
ANIP
ANI Pharmaceuticals, Inc.
|
$80.71 | $109.25 | $1.8B | 49.50x | $0.00 | 0% | 1.97x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$61.14 | $89.74 | $11.7B | 22.91x | $0.00 | 0% | 3.88x |
|
CRMD
CorMedix, Inc.
|
$11.98 | $19.00 | $943.9M | 5.84x | $0.00 | 0% | 4.03x |
|
GILD
Gilead Sciences, Inc.
|
$125.19 | $132.38 | $155.3B | 19.39x | $0.79 | 2.52% | 5.42x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
FOLD
Amicus Therapeutics, Inc.
|
65.77% | 0.379 | 18.22% | 1.91x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
5.64% | 2.330 | 1.52% | 2.70x |
|
ANIP
ANI Pharmaceuticals, Inc.
|
55.53% | -0.550 | 30.7% | 2.40x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
9.17% | -0.764 | 5.87% | 2.84x |
|
CRMD
CorMedix, Inc.
|
1.16% | 3.481 | 0.48% | 1.60x |
|
GILD
Gilead Sciences, Inc.
|
53.66% | 0.042 | 18.1% | 1.16x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
FOLD
Amicus Therapeutics, Inc.
|
$147.7M | $34.3M | -2.18% | -7.02% | 20.27% | $35.3M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257M | $35.8M | 31.98% | 34.23% | 12.83% | $73.9M |
|
ANIP
ANI Pharmaceuticals, Inc.
|
$111.8M | $22.8M | 3.31% | 8.22% | 10.02% | $37.9M |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$641.8M | $184.9M | 8.12% | 8.99% | 23.5% | $334.9M |
|
CRMD
CorMedix, Inc.
|
$93.1M | $51.3M | 94.54% | 95.25% | 49.24% | $30.4M |
|
GILD
Gilead Sciences, Inc.
|
$6.2B | $3.5B | 18.17% | 41.48% | 45.34% | $4B |
Amicus Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns FOLD or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of 10.24% compared to Amicus Therapeutics, Inc.'s net margin of 25.76%. Amicus Therapeutics, Inc.'s return on equity of -7.02% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23%.
Company Gross Margin Earnings Per Share Invested Capital FOLDAmicus Therapeutics, Inc.87.38% $0.06 $673.2M ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M -
What do Analysts Say About FOLD or ACAD?
Amicus Therapeutics, Inc. has a consensus price target of $15.25, signalling upside risk potential of 7.32%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $29.79 which suggests that it could grow by 6.16%. Given that Amicus Therapeutics, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Amicus Therapeutics, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings FOLDAmicus Therapeutics, Inc.3 4 0 ACADACADIA Pharmaceuticals, Inc.9 6 1 -
Is FOLD or ACAD More Risky?
Amicus Therapeutics, Inc. has a beta of 0.463, which suggesting that the stock is 53.675% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.670, suggesting its less volatile than the S&P 500 by 32.982%.
-
Which is a Better Dividend Stock FOLD or ACAD?
Amicus Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amicus Therapeutics, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FOLD or ACAD?
Amicus Therapeutics, Inc. quarterly revenues are $169.1M, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $278.6M. Amicus Therapeutics, Inc.'s net income of $17.3M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $71.8M. Notably, Amicus Therapeutics, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 17.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amicus Therapeutics, Inc. is 7.27x versus 4.48x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FOLDAmicus Therapeutics, Inc.7.27x -- $169.1M $17.3M ACADACADIA Pharmaceuticals, Inc.4.48x 17.91x $278.6M $71.8M
-
Which has Higher Returns FOLD or ANIP?
ANI Pharmaceuticals, Inc. has a net margin of 10.24% compared to Amicus Therapeutics, Inc.'s net margin of 10.59%. Amicus Therapeutics, Inc.'s return on equity of -7.02% beat ANI Pharmaceuticals, Inc.'s return on equity of 8.22%.
Company Gross Margin Earnings Per Share Invested Capital FOLDAmicus Therapeutics, Inc.87.38% $0.06 $673.2M ANIPANI Pharmaceuticals, Inc.49.07% $1.13 $1.1B -
What do Analysts Say About FOLD or ANIP?
Amicus Therapeutics, Inc. has a consensus price target of $15.25, signalling upside risk potential of 7.32%. On the other hand ANI Pharmaceuticals, Inc. has an analysts' consensus of $109.25 which suggests that it could grow by 35.34%. Given that ANI Pharmaceuticals, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe ANI Pharmaceuticals, Inc. is more attractive than Amicus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings FOLDAmicus Therapeutics, Inc.3 4 0 ANIPANI Pharmaceuticals, Inc.4 1 0 -
Is FOLD or ANIP More Risky?
Amicus Therapeutics, Inc. has a beta of 0.463, which suggesting that the stock is 53.675% less volatile than S&P 500. In comparison ANI Pharmaceuticals, Inc. has a beta of 0.484, suggesting its less volatile than the S&P 500 by 51.639%.
-
Which is a Better Dividend Stock FOLD or ANIP?
Amicus Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ANI Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amicus Therapeutics, Inc. pays -- of its earnings as a dividend. ANI Pharmaceuticals, Inc. pays out 8.77% of its earnings as a dividend. ANI Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios FOLD or ANIP?
Amicus Therapeutics, Inc. quarterly revenues are $169.1M, which are smaller than ANI Pharmaceuticals, Inc. quarterly revenues of $227.8M. Amicus Therapeutics, Inc.'s net income of $17.3M is lower than ANI Pharmaceuticals, Inc.'s net income of $24.1M. Notably, Amicus Therapeutics, Inc.'s price-to-earnings ratio is -- while ANI Pharmaceuticals, Inc.'s PE ratio is 49.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amicus Therapeutics, Inc. is 7.27x versus 1.97x for ANI Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FOLDAmicus Therapeutics, Inc.7.27x -- $169.1M $17.3M ANIPANI Pharmaceuticals, Inc.1.97x 49.50x $227.8M $24.1M
-
Which has Higher Returns FOLD or BMRN?
BioMarin Pharmaceutical, Inc. has a net margin of 10.24% compared to Amicus Therapeutics, Inc.'s net margin of -3.91%. Amicus Therapeutics, Inc.'s return on equity of -7.02% beat BioMarin Pharmaceutical, Inc.'s return on equity of 8.99%.
Company Gross Margin Earnings Per Share Invested Capital FOLDAmicus Therapeutics, Inc.87.38% $0.06 $673.2M BMRNBioMarin Pharmaceutical, Inc.81.58% -$0.16 $6.7B -
What do Analysts Say About FOLD or BMRN?
Amicus Therapeutics, Inc. has a consensus price target of $15.25, signalling upside risk potential of 7.32%. On the other hand BioMarin Pharmaceutical, Inc. has an analysts' consensus of $89.74 which suggests that it could grow by 50.87%. Given that BioMarin Pharmaceutical, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe BioMarin Pharmaceutical, Inc. is more attractive than Amicus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings FOLDAmicus Therapeutics, Inc.3 4 0 BMRNBioMarin Pharmaceutical, Inc.13 7 0 -
Is FOLD or BMRN More Risky?
Amicus Therapeutics, Inc. has a beta of 0.463, which suggesting that the stock is 53.675% less volatile than S&P 500. In comparison BioMarin Pharmaceutical, Inc. has a beta of 0.299, suggesting its less volatile than the S&P 500 by 70.071%.
-
Which is a Better Dividend Stock FOLD or BMRN?
Amicus Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioMarin Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amicus Therapeutics, Inc. pays -- of its earnings as a dividend. BioMarin Pharmaceutical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FOLD or BMRN?
Amicus Therapeutics, Inc. quarterly revenues are $169.1M, which are smaller than BioMarin Pharmaceutical, Inc. quarterly revenues of $786.8M. Amicus Therapeutics, Inc.'s net income of $17.3M is higher than BioMarin Pharmaceutical, Inc.'s net income of -$30.7M. Notably, Amicus Therapeutics, Inc.'s price-to-earnings ratio is -- while BioMarin Pharmaceutical, Inc.'s PE ratio is 22.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amicus Therapeutics, Inc. is 7.27x versus 3.88x for BioMarin Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FOLDAmicus Therapeutics, Inc.7.27x -- $169.1M $17.3M BMRNBioMarin Pharmaceutical, Inc.3.88x 22.91x $786.8M -$30.7M
-
Which has Higher Returns FOLD or CRMD?
CorMedix, Inc. has a net margin of 10.24% compared to Amicus Therapeutics, Inc.'s net margin of 49.9%. Amicus Therapeutics, Inc.'s return on equity of -7.02% beat CorMedix, Inc.'s return on equity of 95.25%.
Company Gross Margin Earnings Per Share Invested Capital FOLDAmicus Therapeutics, Inc.87.38% $0.06 $673.2M CRMDCorMedix, Inc.89.26% $1.26 $378.5M -
What do Analysts Say About FOLD or CRMD?
Amicus Therapeutics, Inc. has a consensus price target of $15.25, signalling upside risk potential of 7.32%. On the other hand CorMedix, Inc. has an analysts' consensus of $19.00 which suggests that it could grow by 58.6%. Given that CorMedix, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe CorMedix, Inc. is more attractive than Amicus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings FOLDAmicus Therapeutics, Inc.3 4 0 CRMDCorMedix, Inc.4 0 0 -
Is FOLD or CRMD More Risky?
Amicus Therapeutics, Inc. has a beta of 0.463, which suggesting that the stock is 53.675% less volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.322, suggesting its more volatile than the S&P 500 by 32.155%.
-
Which is a Better Dividend Stock FOLD or CRMD?
Amicus Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amicus Therapeutics, Inc. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FOLD or CRMD?
Amicus Therapeutics, Inc. quarterly revenues are $169.1M, which are larger than CorMedix, Inc. quarterly revenues of $104.3M. Amicus Therapeutics, Inc.'s net income of $17.3M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Amicus Therapeutics, Inc.'s price-to-earnings ratio is -- while CorMedix, Inc.'s PE ratio is 5.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amicus Therapeutics, Inc. is 7.27x versus 4.03x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FOLDAmicus Therapeutics, Inc.7.27x -- $169.1M $17.3M CRMDCorMedix, Inc.4.03x 5.84x $104.3M $108.6M
-
Which has Higher Returns FOLD or GILD?
Gilead Sciences, Inc. has a net margin of 10.24% compared to Amicus Therapeutics, Inc.'s net margin of 39.21%. Amicus Therapeutics, Inc.'s return on equity of -7.02% beat Gilead Sciences, Inc.'s return on equity of 41.48%.
Company Gross Margin Earnings Per Share Invested Capital FOLDAmicus Therapeutics, Inc.87.38% $0.06 $673.2M GILDGilead Sciences, Inc.79.84% $2.43 $46.4B -
What do Analysts Say About FOLD or GILD?
Amicus Therapeutics, Inc. has a consensus price target of $15.25, signalling upside risk potential of 7.32%. On the other hand Gilead Sciences, Inc. has an analysts' consensus of $132.38 which suggests that it could grow by 5.74%. Given that Amicus Therapeutics, Inc. has higher upside potential than Gilead Sciences, Inc., analysts believe Amicus Therapeutics, Inc. is more attractive than Gilead Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings FOLDAmicus Therapeutics, Inc.3 4 0 GILDGilead Sciences, Inc.16 8 0 -
Is FOLD or GILD More Risky?
Amicus Therapeutics, Inc. has a beta of 0.463, which suggesting that the stock is 53.675% less volatile than S&P 500. In comparison Gilead Sciences, Inc. has a beta of 0.318, suggesting its less volatile than the S&P 500 by 68.175%.
-
Which is a Better Dividend Stock FOLD or GILD?
Amicus Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences, Inc. offers a yield of 2.52% to investors and pays a quarterly dividend of $0.79 per share. Amicus Therapeutics, Inc. pays -- of its earnings as a dividend. Gilead Sciences, Inc. pays out 805.23% of its earnings as a dividend.
-
Which has Better Financial Ratios FOLD or GILD?
Amicus Therapeutics, Inc. quarterly revenues are $169.1M, which are smaller than Gilead Sciences, Inc. quarterly revenues of $7.8B. Amicus Therapeutics, Inc.'s net income of $17.3M is lower than Gilead Sciences, Inc.'s net income of $3.1B. Notably, Amicus Therapeutics, Inc.'s price-to-earnings ratio is -- while Gilead Sciences, Inc.'s PE ratio is 19.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amicus Therapeutics, Inc. is 7.27x versus 5.42x for Gilead Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FOLDAmicus Therapeutics, Inc.7.27x -- $169.1M $17.3M GILDGilead Sciences, Inc.5.42x 19.39x $7.8B $3.1B
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 24
Applied Optoelectronics, Inc. [AAOI] is up 3.18% over the past day.
Buy
85
HUT alert for Dec 24
Hut 8 Corp. [HUT] is up 1.39% over the past day.
Buy
63
GPCR alert for Dec 24
Structure Therapeutics, Inc. [GPCR] is down 2.67% over the past day.
